Revenue reaches
CMS establishes Medicare hospital outpatient payment for diagnostic QTscan examinations, effective
2026 revenue guidance adjusted to approximately
Conference call today at
“Our third-quarter results demonstrate the continued growth of
We have also doubled our manufacturing capacity with the relocation to our new 22,000-square-foot facility in
Third Quarter and Recent Business Highlights
Our progress includes:
- Strong commercial growth: Third-quarter revenue increased 75% year over year to
$7.3 million , with 15 Breast Acoustic CT scanners sold. For the first nine months of 2026, revenue reached$21.3 million , with 43 scanners sold, compared with 23 in the prior-year period. - Expanded
U.S . commercialization: Strengthened our direct sales organization, expanded our pipeline of qualified opportunities, and began receiving direct customer purchase orders, while continuing our partnership with NXC Imaging. - Broader access to
U.S . healthcare systems: Recognition at Premier's Supplier Innovation Celebration and a national group purchasing agreement secured by NXC Imaging, providing a streamlined procurement pathway to Premier's network of nearly 4,400 hospitals and health systems. - Major Medicare reimbursement milestone: On
November 4, 2026 , theCenters for Medicare & Medicaid Services (CMS) reversed its earlier proposed nonpayment decision and established separate Medicare hospital outpatient payment for medically necessary diagnostic QTscan examinations, effectiveJanuary 1, 2027 . CMS assigned CPT Category III code 1079T to Ambulatory Payment Classification (APC) 5522, with payment status indicator S. Together with theOctober 1 implementation of the dedicated CPT code, this decision establishes a Medicare hospital outpatient payment pathway for eligible diagnostic QTscan examinations. The Company has developed a comprehensive coding and billing guide to support healthcare providers. This Medicare payment pathway applies to eligible, medically necessary diagnostic QTscan examinations and does not extend to routine breast cancer screening. - Clinical adoption and evidence generation: Expanded radiologist training and continued clinical research aligned with our payer strategy, focusing on supplemental imaging for women with dense breasts, quantitative monitoring of treatment response, and diagnostic applications for high-risk women.
- International expansion: Secured our first major
United Arab Emirates (“UAE”) hospital order from American Hospital Dubai through our local distributor,Al Naghi Medical , received regulatory authorization inIsrael andBahrain , and advanced plans for clinical collaborations inIsrael and theUAE . - Operational and quality milestones: Completed our relocation to the approximately 22,000-square-foot
Petaluma headquarters and manufacturing facility, which doubled our manufacturing capacity, and successfully completed our first routineFDA inspection with zero FormFDA 483 observations. - Technology and platform development: Advanced our integrated Breast Acoustic CT platform through improvements in image reconstruction, quantitative analysis, the QTI-Olea Viewer, and QTI Precision Pathway™ cloud capabilities.
Third Quarter 2026 Financial Results
Revenue for the third quarter of 2026 was
Gross profit was
Total operating expenses were
Operating loss was
As of
2026 Revenue Outlook
The Company is revising its full-year 2026 revenue guidance to approximately
The Company’s
Conference Call and Webcast
Non-GAAP Financial Measures
Some of the financial information and data contained in this press release, such as EBITDA and Adjusted EBITDA, have not been prepared in accordance with GAAP. To supplement our unaudited condensed consolidated financial statements, which are prepared and presented in accordance with GAAP in our press release, we also report certain non-GAAP financial measures. A “non-GAAP financial measure” refers to a numerical measure of a company’s historical or future financial performance, financial position, or cash flows that excludes (or includes) amounts that are included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in such company’s financial statements. Non-GAAP financial measures should not be considered in isolation or as a substitute for the relevant GAAP measures and should be read in conjunction with information presented on a GAAP basis. Because not all companies use identical calculations, our presentation of non-GAAP measures may not be comparable to other similarly titled measures of other companies.
The presentation of these financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP and should not be considered measures of QT Imaging’s liquidity. Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. In particular, many of the adjustments to our GAAP financial measures reflect the exclusion of certain items, as defined in our non-GAAP definitions below, which are recurring and will be reflected in our financial results for the foreseeable future. In addition, these measures may be different from non-GAAP financial measures used by other companies, even where similarly titled, limiting their usefulness for comparison purposes and therefore should not be used to compare QT Imaging’s performance to that of other companies. We endeavor to compensate for the limitation of the non-GAAP financial measures presented by also providing the most directly comparable GAAP measures and descriptions of the reconciling items and adjustments to derive the non-GAAP financial measures.
We believe these non-GAAP financial measures provide investors and analysts with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key measures used by management to operate and analyze our business over different periods of time.
EBITDA is defined as net loss before interest expense, income tax expense, depreciation, and amortization. Adjusted EBITDA is defined as EBITDA further adjusted for other expense (income), change in fair value of the warrant, derivative, and earnout liabilities, loss on issuance of debt, loss on debt extinguishment and modification, and stock-based compensation. Similar excluded expenses may be incurred in future periods when calculating these measures.
Management does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s consolidated financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which expense and income items are excluded or included in determining these non-GAAP financial measures.
Management uses EBITDA and Adjusted EBITDA as non-GAAP performance measures, which are defined above and reconciled to net loss, the most directly comparable GAAP measure, in the tables below.
About
Breast Acoustic CT™ is a trademark of an affiliate of
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the ability of providers to use the new CPT code and obtain reimbursement, including from Medicare, QT Imaging’s quality and regulatory compliance and its ability to scale manufacturing, expand commercialization in the
[Financial tables below]
Summary of Results For the Three and Nine Months Ended (Unaudited) | |||||||||||||||
| Three Months Ended |
| Nine Months Ended | ||||||||||||
$ thousands (except per share amounts) |
| 2026 |
|
|
| 2025 |
|
|
| 2026 |
|
|
| 2025 |
|
Revenue | $ | 7,340 |
|
| $ | 4,192 |
|
| $ | 21,305 |
|
| $ | 10,650 |
|
Cost of revenue |
| 4,311 |
|
|
| 2,389 |
|
|
| 12,544 |
|
|
| 5,208 |
|
Gross profit |
| 3,029 |
|
|
| 1,803 |
|
|
| 8,761 |
|
|
| 5,442 |
|
Operating expenses: |
|
|
|
|
|
|
| ||||||||
Research and development |
| 1,724 |
|
|
| 939 |
|
|
| 5,072 |
|
|
| 2,692 |
|
Selling, general and administrative |
| 3,753 |
|
|
| 2,516 |
|
|
| 10,350 |
|
|
| 6,487 |
|
Total operating expenses |
| 5,477 |
|
|
| 3,455 |
|
|
| 15,422 |
|
|
| 9,179 |
|
Loss from operations |
| (2,448 | ) |
|
| (1,652 | ) |
|
| (6,661 | ) |
|
| (3,737 | ) |
Interest and other income (expense), net: |
|
|
|
|
|
|
| ||||||||
Interest expense, net |
| (328 | ) |
|
| (565 | ) |
|
| (2,003 | ) |
|
| (1,635 | ) |
Other (expense) income, net |
| (2 | ) |
|
| 16 |
|
|
| (10 | ) |
|
| 40 |
|
Change in fair value of warrant liability |
| 71 |
|
|
| (80 | ) |
|
| (13 | ) |
|
| (3,581 | ) |
Change in fair value of derivative liability |
| — |
|
|
| — |
|
|
| — |
|
|
| 101 |
|
Change in fair value of earnout liability |
| 2,410 |
|
|
| (2,230 | ) |
|
| 2,210 |
|
|
| (2,070 | ) |
Loss on issuance of debt |
| — |
|
|
| — |
|
|
| — |
|
|
| (6,640 | ) |
Loss on debt extinguishment and modification |
| — |
|
|
| (46 | ) |
|
| (8,294 | ) |
|
| (2,170 | ) |
Total interest and other income (expense), net |
| 2,151 |
|
|
| (2,905 | ) |
|
| (8,110 | ) |
|
| (15,955 | ) |
Loss before income tax expense |
| (297 | ) |
|
| (4,557 | ) |
|
| (14,771 | ) |
|
| (19,692 | ) |
Income tax expense |
| — |
|
|
| — |
|
|
| 2 |
|
|
| 3 |
|
Net loss | $ | (297 | ) |
| $ | (4,557 | ) |
| $ | (14,773 | ) |
| $ | (19,695 | ) |
Net loss attributable to common stockholders | $ | (297 | ) |
| $ | (4,557 | ) |
| $ | (14,773 | ) |
| $ | (19,695 | ) |
|
|
|
|
|
|
|
| ||||||||
Net loss per share - basic and diluted | $ | (0.02 | ) |
| $ | (0.47 | ) |
| $ | (0.99 | ) |
| $ | (2.09 | ) |
|
|
|
|
|
|
|
| ||||||||
Weighted-average shares outstanding |
| 15,895 |
|
|
| 9,602 |
|
|
| 14,849 |
|
|
| 9,415 |
|
EBITDA and Adjusted EBITDA For the Three and Nine Months Ended (Unaudited) | |||||||||||||||
| Three Months Ended |
| Nine Months Ended | ||||||||||||
$ thousands |
| 2026 |
|
|
| 2025 |
|
|
| 2026 |
|
|
| 2025 |
|
Net loss | $ | (297 | ) |
| $ | (4,557 | ) |
| $ | (14,773 | ) |
| $ | (19,695 | ) |
Income tax expense |
| — |
|
|
| — |
|
|
| 2 |
|
|
| 3 |
|
Interest expense, net |
| 328 |
|
|
| 565 |
|
|
| 2,003 |
|
|
| 1,635 |
|
Depreciation and amortization |
| 55 |
|
|
| 40 |
|
|
| 96 |
|
|
| 115 |
|
EBITDA |
| 86 |
|
|
| (3,952 | ) |
|
| (12,672 | ) |
|
| (17,942 | ) |
Other expense (income), net |
| 2 |
|
|
| (16 | ) |
|
| 10 |
|
|
| (40 | ) |
Change in fair value of warrant liability (1) |
| (71 | ) |
|
| 80 |
|
|
| 13 |
|
|
| 3,581 |
|
Change in fair value of derivative liability (2) |
| — |
|
|
| — |
|
|
| — |
|
|
| (101 | ) |
Change in fair value of earnout liability (3) |
| (2,410 | ) |
|
| 2,230 |
|
|
| (2,210 | ) |
|
| 2,070 |
|
Loss on issuance of debt (4) |
| — |
|
|
| — |
|
|
| — |
|
|
| 6,640 |
|
Loss on debt extinguishment and modification (5) |
| — |
|
|
| 46 |
|
|
| 8,294 |
|
|
| 2,170 |
|
Stock-based compensation |
| 731 |
|
|
| 199 |
|
|
| 1,780 |
|
|
| 519 |
|
Adjusted EBITDA | $ | (1,662 | ) |
| $ | (1,413 | ) |
| $ | (4,785 | ) |
| $ | (3,103 | ) |
(1) |
| The change in fair value of warrant liability during the three and nine months ended |
|
|
|
(2) |
| The change in fair value of derivative liability during the nine months ended |
|
|
|
(3) |
| The earnout liability relates to the contingent consideration for the Merger Earnout Consideration Shares pursuant to the Business Combination Agreement dated |
|
|
|
(4) |
| Upon the issuance of the Lynrock Lake Term Loan, which closed on |
|
|
|
(5) |
| The Company recorded a loss on debt extinguishment of |
Consolidated Balance Sheets As of (Unaudited) | |||||||
$ in thousands |
| ||||||
Assets |
|
|
| ||||
Current assets: |
|
|
| ||||
Cash and cash equivalents | $ | 8,124 |
|
| $ | 10,412 |
|
Restricted cash and cash equivalents |
| 300 |
|
|
| 50 |
|
Accounts receivable, net |
| 7,344 |
|
|
| 5,781 |
|
Inventory |
| 11,483 |
|
|
| 5,027 |
|
Prepaid expenses and other current assets |
| 954 |
|
|
| 821 |
|
Total current assets |
| 28,205 |
|
|
| 22,091 |
|
|
|
|
| ||||
Property and equipment, net |
| 889 |
|
|
| 318 |
|
Operating lease right-of-use assets, net |
| 1,386 |
|
|
| 573 |
|
Other assets |
| 39 |
|
|
| 39 |
|
Total assets | $ | 30,519 |
|
| $ | 23,021 |
|
|
|
|
| ||||
Liabilities and Stockholders' Equity |
|
|
| ||||
Current liabilities: |
|
|
| ||||
Accounts payable | $ | 3,681 |
|
| $ | 3,580 |
|
Accrued expenses and other current liabilities |
| 5,939 |
|
|
| 3,825 |
|
Current maturities of long-term debt |
| — |
|
|
| 9 |
|
Operating lease liabilities, current |
| 541 |
|
|
| 454 |
|
Total current liabilities |
| 10,161 |
|
|
| 7,868 |
|
Long-term debt |
| 11,397 |
|
|
| 683 |
|
Related party notes payable |
| 3,895 |
|
|
| 3,895 |
|
Operating lease liabilities |
| 906 |
|
|
| 203 |
|
Warrant liability |
| 116 |
|
|
| 103 |
|
Earnout liability |
| — |
|
|
| 2,210 |
|
Other liabilities |
| 1,395 |
|
|
| 1,614 |
|
Total liabilities |
| 27,870 |
|
|
| 16,576 |
|
|
|
|
| ||||
Stockholders’ equity: |
|
|
| ||||
Common stock |
| 1 |
|
|
| 1 |
|
Additional paid-in capital |
| 70,445 |
|
|
| 59,468 |
|
Accumulated deficit |
| (67,797 | ) |
|
| (53,024 | ) |
Total stockholders’ equity |
| 2,649 |
|
|
| 6,445 |
|
Total liabilities and stockholders’ equity | $ | 30,519 |
|
| $ | 23,021 |
|
Consolidated Statements of Cash Flows For the Nine Months Ended (Unaudited) | |||||||
| Nine Months Ended | ||||||
$ in thousands |
| 2026 |
|
|
| 2025 |
|
Cash flows from operating activities: |
|
|
| ||||
Net loss | $ | (14,773 | ) |
| $ | (19,695 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
| ||||
Depreciation and amortization |
| 96 |
|
|
| 115 |
|
Stock-based compensation |
| 1,780 |
|
|
| 519 |
|
Loss on issuance of debt |
| — |
|
|
| 6,640 |
|
Loss on debt extinguishment and modification |
| 8,294 |
|
|
| 2,170 |
|
Non-cash interest |
| 1,123 |
|
|
| 749 |
|
Non-cash operating lease and other |
| (13 | ) |
|
| (31 | ) |
Change in fair value of warrant liability |
| 13 |
|
|
| 3,581 |
|
Change in fair value of derivative liability |
| — |
|
|
| (101 | ) |
Change in fair value of earnout liability |
| (2,210 | ) |
|
| 2,070 |
|
Changes in operating assets and liabilities: |
|
|
| ||||
Accounts receivable |
| (1,573 | ) |
|
| (3,177 | ) |
Inventory |
| (6,781 | ) |
|
| (2,102 | ) |
Prepaid expenses and other current assets |
| (132 | ) |
|
| (298 | ) |
Accounts payable |
| 318 |
|
|
| 1,072 |
|
Accrued expenses and other current liabilities |
| 2,102 |
|
|
| 1,831 |
|
Other liabilities |
| 1,078 |
|
|
| 799 |
|
Net cash used in operating activities |
| (10,678 | ) |
|
| (5,858 | ) |
|
|
|
| ||||
Cash flows from investing activities: |
|
|
| ||||
Purchases of property and equipment |
| (263 | ) |
|
| (47 | ) |
Net cash used in investing activities |
| (263 | ) |
|
| (47 | ) |
|
|
|
| ||||
Cash flows from financing activities: |
|
|
| ||||
Proceeds from sale of common stock and warrants, net of issuance costs |
| 9,045 |
|
|
| 679 |
|
Proceeds from long-term debt, net of issuance costs |
| — |
|
|
| 15,000 |
|
Proceeds from warrant exercises |
| — |
|
|
| 532 |
|
Proceeds from stock option exercises |
| 246 |
|
|
| 75 |
|
Repayment of long-term debt |
| (9 | ) |
|
| (4,688 | ) |
Payments for taxes related to net settlement of equity awards |
| (94 | ) |
|
| — |
|
Payments for stock issuance costs |
| (285 | ) |
|
| — |
|
Repurchase of warrant from |
| — |
|
|
| (5,000 | ) |
Payment of debt issuance costs |
| — |
|
|
| (150 | ) |
Net cash provided by financing activities |
| 8,903 |
|
|
| 6,448 |
|
Net (decrease) increase in cash and cash equivalents and restricted cash and cash equivalents |
| (2,038 | ) |
|
| 543 |
|
Cash and cash equivalents and restricted cash and cash equivalents, beginning balance |
| 10,462 |
|
|
| 1,192 |
|
Cash and cash equivalents and restricted cash and cash equivalents, ending balance | $ | 8,424 |
|
| $ | 1,735 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20261110154045/en/
Investors
CORE IR
ir@qtimaging.com
386-295-2215
Media
CORE IR
pr@qtimaging.com
212-655-0924
Source: